[25] 中 华 医 学 会 肝 病 学 分 会 . 肝 硬 化 诊 治 指 南 [J]. 中 华 肝
脏 病 杂 志 , 2019, 27(11) :846-865. DOI:10.3760/cma.
j.issn.1007-3418.2019.11.008.
[26] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing
consensus in portal hypertension[J]. J Hepatol, 2022, 76(4):959-974.
DOI: 10.1016/j.jhep.2021.12.022.
[27] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno VII criteria for
recompensation in entecavir-treated patients with hepatitis B-related
decompensated cirrhosis[J]. J Hepatol, 2022, 77(6):1564-1572. DOI:
10.1016/j.jhep.2022.07.037.
[28] He Z, Zhou J, Tian Y, et al. Two-year free of complications
during antiviral therapy predicts stable re-compensation
in immediate-treatment HBV-related decompensated
cirrhosis[J]. Scand J Gastroenterol, 2023, 58(4):403-411. DOI:
10.1080/00365521.2022.2132532.
[29] Huppert LA, Walker Z, Li M, et al. Clinical characteristics
and outcomes in patients with metastatic breast cancer and
pseudocirrhosis: a single center retrospective cohort study[J]. Breast
Cancer Res Treat, 2023, 197(1):137-148. DOI: 10.1007/s10549-022-
06771-5.
[30] Zhang X, Song J, Zhang Y, et al. Baveno VII algorithm outperformed
other models in ruling out high-risk varices in individuals with HBV-
related cirrhosis[J]. J Hepatol, 2023, 78(3):574-583. DOI: 10.1016/
j.jhep.2022.10.030.
[31] Chen S, Wang B, Zhou J, et al. A new glutamine synthetase index to
evaluate hepatic lobular restoration in advanced fibrosis during anti-
HBV therapy[J]. J Med Virol, 2023, 95(2):e28555. DOI: 10.1002/
jmv.28555.
[32] Liu YQ, Zhang C, Li JW, et al. An-Luo-Hua-Xian pill improves the
regression of liver fibrosis in chronic hepatitis B patients treated
with entecavir[J]. J Clin Transl Hepatol, 2023, 11(2):304-313. DOI:
10.14218/JCTH.2022.00091.
[33] Rong G, Chen Y, Yu Z, et al. Synergistic effect of biejia-ruangan
on fibrosis regression in patients with chronic hepatitis B treated
with entecavir: a multicenter, randomized, double-blind, placebo-
controlled trial[J]. J Infect Dis, 2022, 225(6):1091-1099. DOI:
10.1093/infdis/jiaa266.
[34] Shi K, Liu Y, Wang X, et al. Adjuvant Fuzheng Huayu capsule
reduces the incidence of hepatocellular carcinoma in patients with
hepatitis B-caused cirrhosis[J]. Evid Based Complement Alternat
Med, 2020, 2020:8826091. DOI: 10.1155/2020/8826091.
[35] Ji D, Chen Y, Bi J, et al. Entecavir plus Biejia-Ruangan compound
reduces the risk of hepatocellular carcinoma in Chinese patients
with chronic hepatitis B[J]. J Hepatol, 2022, 77(6):1515-1524. DOI:
10.1016/j.jhep.2022.07.018.
[36] Dai YK, Fan HN, Huang K, et al. Baseline metabolites could predict
responders with hepatitis B virus-related liver fibrosis for entecavir
or combined with FuzhengHuayu tablet[J]. World J Hepatol, 2023,
15(9):1043-1059. DOI: 10.4254/wjh.v15.i9.1043.
[37] Turco L, Reiberger T, Vitale G, et al. Carvedilol as the new non-
selective beta-blocker of choice in patients with cirrhosis and portal
hypertension[J]. Liver Int, 2023, 43(6):1183-1194. DOI: 10.1111/
liv.15559.
[38] Wang B, Zhou J, Wu X, et al. Carvedilol plus NUC for patients
with HBV-compensated cirrhosis under virological suppression: a
randomized open-label trial[J]. Am J Gastroenterol, 2023 Dec 7.
DOI: 10.14309/ajg.0000000000002569. Epub ahead of print.
[39] Paar M, Fengler VH, Reibnegger G, et al. Determination of binding
characteristics as a measure for effective albumin using different
methods[J]. Biochim Biophys Acta Gen Subj, 2023, 1867(9):130427.
DOI: 10.1016/j.bbagen.2023.130427.
[40] Baldassarre M, Naldi M, Zaccherini G, et al. Determination of
effective albumin in patients with decompensated cirrhosis: clinical
and prognostic implications[J]. Hepatology, 2021, 74(4):2058-2073.
DOI: 10.1002/hep.31798.
[41] Zacharias HD, Kamel F, Tan J, et al. Rifaximin for prevention and
treatment of hepatic encephalopathy in people with cirrhosis[J].
Cochrane Database Syst Rev, 2023, 7(7):CD011585. DOI:
10.1002/14651858.CD011585.pub2.
[42] Noureddin M, Harrison SA. NASH cirrhosis trials and major adverse
liver outcomes: big data needed[J]. J Hepatol, 2023, 78(1):5-7. DOI:
10.1016/j.jhep.2022.10.022.
评论
网友评论:
共评论。点击查看